's () CFO Nick Wykeman talks Proactive London's Andrew Scott through their trading update for the year to the end of June 2019.
He says net revenue for the year's expected to be £73.7mln, up 8% on last year, while cash at the end of June was £27.4mln.
That means the group has the funds to fully finance from existing resources the phase III clinical trial of its new short-form grass allergy inoculation due to start next autumn.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE